1. Home
  2. IFN vs IMMX Comparison

IFN vs IMMX Comparison

Compare IFN & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo India Fund Inc. (The)

IFN

India Fund Inc. (The)

HOLD

Current Price

$11.60

Market Cap

540.6M

Sector

Finance

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$9.38

Market Cap

629.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFN
IMMX
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
540.6M
629.3M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
IFN
IMMX
Price
$11.60
$9.38
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$19.20
AVG Volume (30 Days)
175.3K
1.6M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.72
$1.94
52 Week High
$16.60
$11.61

Technical Indicators

Market Signals
Indicator
IFN
IMMX
Relative Strength Index (RSI) 60.76 58.15
Support Level $10.84 $7.99
Resistance Level $11.79 $10.61
Average True Range (ATR) 0.17 0.65
MACD 0.10 0.10
Stochastic Oscillator 96.74 87.11

Price Performance

Historical Comparison
IFN
IMMX

About IFN India Fund Inc. (The)

India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: